Moors & Cabot’s Pfizer PFE Stock Holding History

Moors & Cabot’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-100	Closed	-$2K	–	892
2022 Q1	$2K	Buy	+100	New	+$5.19K	﹤0.01%	893

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Moors & Cabot's PFE Position: Q2 2026 in Review

Moors & Cabot increased its Pfizer (PFE) stake by 4.3% in Q2 2026, buying an estimated $329K and bringing the position to 307,330 shares worth $7.4M. The position accounts for 0.29% of the portfolio, ranked #70.

Moors & Cabot first reported a position in PFE in Q1 2014 and has held it in 50 quarters since. The position peaked at $31.5M in Q3 2021. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Moors & Cabot held 307,330 shares of Pfizer worth $7.4M as of Q2 2026.
Moors & Cabot bought 12,563 Pfizer shares in Q2 2026, an estimated $329K.
Pfizer made up 0.29% of Moors & Cabot's portfolio in Q2 2026, its #70 holding.
Moors & Cabot first reported a position in Pfizer in Q1 2014 and has held it in 50 quarters since.
Moors & Cabot's Pfizer position peaked at $31.5M in Q3 2021.
2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.